Menu

Blog

Jan 14, 2019

UNITY Biotechnologies Selects a New Senolytic Candidate

Posted by in categories: biotech/medical, life extension

Another senolytic drug candidate has entered development at Unity Biotechnologies. The purpose of senolytics is to clear the body of harmful senescent cells, which accumulate with age and encourage age-related diseases to develop.

A new treatment for age-related diseases of the eye

Recently, UNITY Biotechnologies announced the selection of a new lead drug, UBX1967, with the goal of treating a range of age-related diseases of the eye. This is the second drug in the pipeline of this $677 million company. This drug is unique in the world of eye treatment; it targets and destroys senescent cells, making it a senolytic that targets one of the root causes of aging to treat disease.

Read more

Comments are closed.